TR201904389T4 - Method for producing lipid nucleic acid particles in a sterile manner. - Google Patents
Method for producing lipid nucleic acid particles in a sterile manner. Download PDFInfo
- Publication number
- TR201904389T4 TR201904389T4 TR2019/04389T TR201904389T TR201904389T4 TR 201904389 T4 TR201904389 T4 TR 201904389T4 TR 2019/04389 T TR2019/04389 T TR 2019/04389T TR 201904389 T TR201904389 T TR 201904389T TR 201904389 T4 TR201904389 T4 TR 201904389T4
- Authority
- TR
- Turkey
- Prior art keywords
- nucleic acid
- acid particles
- sterile manner
- producing lipid
- lipid nucleic
- Prior art date
Links
- -1 lipid nucleic acid Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Açıklamada, tek kullanımlık bileşenlerin kullanılmasını içeren aseptik koşullar altından lipit-nükleik asit nanopartiküllerinin kolayca ve tekrar üretilebilir bir şekilde oluşturulmasına yönelik bir proses açıklanmaktadır.The disclosure describes a process for easily and reproducibly forming lipid-nucleic acid nanoparticles under aseptic conditions involving the use of disposable components.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556124P | 2011-11-04 | 2011-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201904389T4 true TR201904389T4 (en) | 2019-04-22 |
Family
ID=47178988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/04389T TR201904389T4 (en) | 2011-11-04 | 2012-11-02 | Method for producing lipid nucleic acid particles in a sterile manner. |
Country Status (21)
Country | Link |
---|---|
US (1) | US8956572B2 (en) |
EP (4) | EP3673898A1 (en) |
JP (3) | JP6133883B2 (en) |
KR (2) | KR102056702B1 (en) |
CN (2) | CN103906503B (en) |
AU (2) | AU2012356239B2 (en) |
CA (2) | CA2853689C (en) |
CY (1) | CY1121495T1 (en) |
DK (1) | DK2773326T3 (en) |
ES (1) | ES2721325T3 (en) |
HR (1) | HRP20190481T1 (en) |
HU (1) | HUE043809T2 (en) |
LT (1) | LT2773326T (en) |
PL (1) | PL2773326T3 (en) |
PT (1) | PT2773326T (en) |
RS (1) | RS58562B1 (en) |
RU (2) | RU2642640C2 (en) |
SI (1) | SI2773326T1 (en) |
TR (1) | TR201904389T4 (en) |
TW (3) | TWI618548B (en) |
WO (2) | WO2013064911A2 (en) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN104531812A (en) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | Engineered nucleic acids and methods of use thereof |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2707251C2 (en) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Modified nucleosides, nucleotides and nucleic acids and use thereof |
US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9320297B2 (en) * | 2012-03-22 | 2016-04-26 | Lemniscate Innovations Llc | Spherification/reverse spherification automated and integrated system and method |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
HUE056014T2 (en) | 2012-06-08 | 2022-01-28 | Nitto Denko Corp | Lipids for therapeutic agent delivery formulations |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
SG11201506116XA (en) | 2013-02-05 | 2015-09-29 | 1Globe Health Inst Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
EP3971287A1 (en) * | 2013-07-11 | 2022-03-23 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015048020A2 (en) * | 2013-09-24 | 2015-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN103599549A (en) * | 2013-11-22 | 2014-02-26 | 大连民族学院 | SiRNA (Small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and preparation method and application thereof |
BR112016024644A2 (en) | 2014-04-23 | 2017-10-10 | Modernatx Inc | nucleic acid vaccines |
JP6782171B2 (en) * | 2014-07-02 | 2020-11-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Encapsulation of messenger RNA |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US10342761B2 (en) * | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
RU2723032C2 (en) * | 2014-12-29 | 2020-06-08 | Бонак Корпорейшн | Composition stably containing a nucleic acid molecule |
AU2016222746A1 (en) | 2015-02-24 | 2017-09-07 | The University Of British Columbia | Continuous flow microfluidic system |
JP2018525209A (en) | 2015-04-28 | 2018-09-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Disposable microfluidic cartridge |
IL288342B2 (en) * | 2015-07-22 | 2024-02-01 | Nitto Denko Corp | Compositions and methods for nanoparticle lyophile forms |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
US9938572B1 (en) * | 2015-09-08 | 2018-04-10 | Raindance Technologies, Inc. | System and method for forming an emulsion |
HRP20220156T1 (en) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
JP6921833B2 (en) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | Human cytomegalovirus vaccine |
JP7080172B2 (en) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | Compositions and Methods for Delivery of Therapeutic Agents |
DK3394030T3 (en) | 2015-12-22 | 2022-03-28 | Modernatx Inc | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR RELEASE OF FUNDS |
ES2919552T3 (en) | 2015-12-23 | 2022-07-27 | Modernatx Inc | Methods of using ox40 ligand-encoding polynucleotides |
CN108778477B (en) | 2016-01-06 | 2022-02-25 | 不列颠哥伦比亚大学 | Bifurcated mixer and methods of use and manufacture thereof |
EP3400023A1 (en) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
US10689873B2 (en) | 2016-03-10 | 2020-06-23 | Lonza Ltd | Customizable facility |
AU2017230823A1 (en) | 2016-03-10 | 2018-09-27 | Lonza Ltd | Customizable facility |
WO2017223135A1 (en) * | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Lipid nanoparticles |
MX2018016389A (en) * | 2016-06-30 | 2019-08-16 | Arbutus Biopharma Corp | Compositions and methods for delivering messenger rna. |
EP3478821A1 (en) | 2016-08-02 | 2019-05-08 | Lonza Ltd | Customizable facility |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US20200283743A1 (en) | 2016-08-17 | 2020-09-10 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
IL264842B (en) * | 2016-08-18 | 2022-08-01 | Troy Bremer | Delivery of urea to cells of the macula and retina using liposome constructs |
EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
KR20190132405A (en) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
MA49421A (en) | 2017-06-15 | 2020-04-22 | Modernatx Inc | RNA FORMULATIONS |
EP3651733A4 (en) * | 2017-07-10 | 2021-04-07 | ImmunoVaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
WO2019027055A1 (en) | 2017-08-04 | 2019-02-07 | 協和発酵キリン株式会社 | Nucleic-acid-containing lipid nanoparticles |
JP2019043216A (en) | 2017-08-30 | 2019-03-22 | いすゞ自動車株式会社 | Steering device |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
SG11202002579SA (en) | 2017-10-20 | 2020-05-28 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
EP3705179B1 (en) * | 2017-11-01 | 2024-05-22 | Osaka University | Method and system for producing lipid particles having desired particle diameter |
JP7103726B2 (en) * | 2017-11-09 | 2022-07-20 | イミューノヴァクシーン テクノロジーズ インコーポレイテッド | Methods for preparations comprising sizing pharmaceutical compositions, lipid vesicle particles, and their use. |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
WO2019204451A1 (en) * | 2018-04-17 | 2019-10-24 | Carnegie Mellon University | Enhanced lipid nanoparticle drug delivery using a negatively charged polymer |
WO2020047061A1 (en) * | 2018-08-29 | 2020-03-05 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
MA53650A (en) | 2018-09-19 | 2021-07-28 | Modernatx Inc | PEG LIPIDS AND THEIR USES |
MA53652A (en) | 2018-09-19 | 2021-07-28 | Modernatx Inc | HIGH PURITY PEG LIPIDS AND THEIR USES |
WO2020061457A1 (en) * | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
CA3113449A1 (en) * | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
JP2022512578A (en) | 2018-10-09 | 2022-02-07 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | Compositions and systems comprising transfection competent vesicles free of organic solvents and no degradation agents and related methods. |
CA3112837A1 (en) * | 2018-10-19 | 2020-04-23 | Translate Bio, Inc. | Pumpless encapsulation of messenger rna |
AU2020214843A1 (en) * | 2019-01-31 | 2021-08-19 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
WO2020191103A1 (en) * | 2019-03-19 | 2020-09-24 | Arcturus Therapeutics, Inc. | Method of making lipid-encapsulated rna nanoparticles |
EP3965738A1 (en) | 2019-05-07 | 2022-03-16 | Universidade do Minho | Method for production of liposomes |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
US20230097090A1 (en) | 2019-08-14 | 2023-03-30 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
CN114929205A (en) | 2019-09-06 | 2022-08-19 | 世代生物公司 | Lipid nanoparticle compositions comprising terminally-blocked DNA and cleavable lipids and methods of use thereof |
JP7271374B2 (en) * | 2019-09-10 | 2023-05-11 | 株式会社東芝 | Analysis method, analysis substrate, analysis kit and analysis device. |
EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
MX2022006033A (en) | 2019-11-22 | 2022-06-22 | Generation Bio Co | Ionizable lipids and nanoparticle compositions thereof. |
KR102409145B1 (en) * | 2020-03-23 | 2022-06-15 | 프레스티지바이오로직스 주식회사 | Buffer Preparation and Transfer System for Production of Antibody Pharmaceuticals |
CN111467321A (en) * | 2020-03-26 | 2020-07-31 | 深圳市新合生物医疗科技有限公司 | Intracellular delivery system of mRNA nucleic acid medicine, preparation method and application |
MX2023002928A (en) | 2020-09-13 | 2023-06-12 | Arcturus Therapeutics Inc | Lipid nanoparticles encapsulation of large rna. |
CN112843019A (en) * | 2021-01-27 | 2021-05-28 | 江苏普瑞康生物医药科技有限公司 | Nucleic acid lipid nanoparticle composition, pharmaceutical preparation containing same, and preparation method and application thereof |
EP4294450A1 (en) * | 2021-02-16 | 2023-12-27 | The Johns Hopkins University | Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection |
WO2022175366A1 (en) | 2021-02-17 | 2022-08-25 | Secoya Technologies | Method for producing lipid nanoparticles and lipid nanoparticles resulting therefrom |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024515080A (en) * | 2021-04-22 | 2024-04-04 | インベンテージ ラボ インコーポレイテッド | Lipid nanoparticle manufacturing method and manufacturing device thereof |
KR20240023420A (en) | 2021-06-14 | 2024-02-21 | 제너레이션 바이오 컴퍼니 | Cationic lipids and compositions thereof |
WO2023057596A1 (en) * | 2021-10-06 | 2023-04-13 | Leon-Nanodrugs Gmbh | Method for preparing lipid nanoparticles |
TW202334080A (en) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | Lipid nanoparticle compositions for delivering circular polynucleotides |
CN116549626A (en) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | Nucleic acid-loaded lipid nanoparticle freeze-dried preparation and preparation method and application thereof |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
KR102475540B1 (en) * | 2022-04-26 | 2022-12-08 | 주식회사 무진메디 | Method and apparatus for manufacturing drug-loaded lipid nanoparticles |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
WO2024119074A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
WO2024129982A2 (en) | 2022-12-15 | 2024-06-20 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
JPH01501228A (en) * | 1986-09-18 | 1989-04-27 | リポソーム テクノロジー,インコーポレイテッド | High concentration liposome treatment method |
US4895452A (en) | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
JPH08512056A (en) * | 1993-06-30 | 1996-12-17 | ジェネンテク・インコーポレイテッド | Method for producing liposomes |
ATE285477T1 (en) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | PRODUCTION OF LIPID-NUCLIC ACID PARTICLES USING A HYDROPHOBIC LIPID-NUCLIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR USE IN GENE TRANSFER |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
US6287591B1 (en) * | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
AU756196B2 (en) | 1998-11-13 | 2003-01-09 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
IL147089A0 (en) | 1999-07-15 | 2002-08-14 | Inex Pharmaceuticals Corp | Methods of preparing lipid-encapsulated therapeutic agents |
US7094423B1 (en) | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
EP1203614A1 (en) | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Process and apparatus for preparing lipid vesicles |
DE60132094T3 (en) * | 2001-10-26 | 2012-02-02 | Octoplus Polyactive Sciences B.V. | Process for the preparation of purified particles |
US7223887B2 (en) | 2001-12-18 | 2007-05-29 | The University Of British Columbia | Multivalent cationic lipids and methods of using same in the production of lipid particles |
US20090191259A1 (en) | 2002-01-09 | 2009-07-30 | Transave, Inc. | Efficient liposomal encapsulation |
US6712963B2 (en) | 2002-06-14 | 2004-03-30 | Scilog, Llc | Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
FR2856940B1 (en) * | 2003-07-04 | 2007-02-09 | Stedim Sa | CLOSED SYSTEM FOR SINGLE USE IN THE MIXING, STORAGE AND HOMOGENIZATION OF LIQUIDS UNDER OWN OR STERILE CONDITIONS |
WO2005090403A2 (en) * | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
EP1773976B2 (en) | 2004-06-04 | 2020-01-01 | Global Life Sciences Solutions USA LLC | Disposable bioreactor systems and methods |
US7410587B2 (en) | 2004-08-03 | 2008-08-12 | Scilog, Inc. | Liquid handling for filtration and preparative chromatography |
US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
AU2006274413B2 (en) | 2005-07-27 | 2013-01-10 | Arbutus Biopharma Corporation | Systems and methods for manufacturing liposomes |
WO2007051303A1 (en) * | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
WO2007117023A1 (en) | 2006-04-11 | 2007-10-18 | Wingturf Co., Ltd. | Process and apparatus for producing liposome dispersion |
EP1920765A1 (en) | 2006-11-07 | 2008-05-14 | Medigene AG | Liposome preparation by single-pass process |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
JP5322476B2 (en) | 2008-03-31 | 2013-10-23 | テルモ株式会社 | Liposome production apparatus and liposome production method |
US8231787B2 (en) | 2008-05-06 | 2012-07-31 | Spf Innovations, Llc | Tangential flow filtration system |
US20110224447A1 (en) * | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
EP2902013A1 (en) | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
WO2010080724A1 (en) * | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
ES2443147T3 (en) * | 2009-01-20 | 2014-02-18 | Med Coat Ab | Coating composition and its use |
FR2943560B1 (en) * | 2009-03-24 | 2011-05-27 | Jean Pascal Zambaux | DISPOSABLE BIOREACTOR AND AGITATOR SYSTEM FOR SINGLE USE |
CN102712935B (en) * | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | Nucleic acid-containing lipid particles and related methods |
NZ600616A (en) * | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
US20130116419A1 (en) * | 2010-01-22 | 2013-05-09 | Daniel Zewge | Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry |
EP3391877A1 (en) | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
RU2769872C2 (en) * | 2011-06-08 | 2022-04-07 | Нитто Денко Корпорейшн | COMPOUNDS FOR TARGETED DRUG DELIVERY AND ENHANCING siRNA ACTIVITY |
-
2012
- 2012-11-02 AU AU2012356239A patent/AU2012356239B2/en active Active
- 2012-11-02 WO PCT/IB2012/002916 patent/WO2013064911A2/en active Application Filing
- 2012-11-02 EP EP19205352.8A patent/EP3673898A1/en not_active Ceased
- 2012-11-02 ES ES12829180T patent/ES2721325T3/en active Active
- 2012-11-02 EP EP12848760.0A patent/EP2773328A2/en not_active Withdrawn
- 2012-11-02 PT PT12829180T patent/PT2773326T/en unknown
- 2012-11-02 HU HUE12829180A patent/HUE043809T2/en unknown
- 2012-11-02 WO PCT/IB2012/003109 patent/WO2013093648A2/en active Application Filing
- 2012-11-02 KR KR1020147014826A patent/KR102056702B1/en active IP Right Grant
- 2012-11-02 RS RS20190426A patent/RS58562B1/en unknown
- 2012-11-02 CA CA2853689A patent/CA2853689C/en active Active
- 2012-11-02 KR KR1020147014822A patent/KR102046968B1/en active IP Right Grant
- 2012-11-02 RU RU2014122433A patent/RU2642640C2/en active
- 2012-11-02 EP EP18209774.1A patent/EP3485875A1/en active Pending
- 2012-11-02 PL PL12829180T patent/PL2773326T3/en unknown
- 2012-11-02 LT LTEP12829180.4T patent/LT2773326T/en unknown
- 2012-11-02 CN CN201280054023.XA patent/CN103906503B/en active Active
- 2012-11-02 SI SI201231557T patent/SI2773326T1/en unknown
- 2012-11-02 AU AU2012330819A patent/AU2012330819B2/en active Active
- 2012-11-02 TR TR2019/04389T patent/TR201904389T4/en unknown
- 2012-11-02 RU RU2014122432A patent/RU2647476C2/en active
- 2012-11-02 JP JP2014540573A patent/JP6133883B2/en active Active
- 2012-11-02 CA CA2853685A patent/CA2853685C/en active Active
- 2012-11-02 CN CN201280054027.8A patent/CN103906504B/en active Active
- 2012-11-02 EP EP12829180.4A patent/EP2773326B1/en active Active
- 2012-11-02 JP JP2014540571A patent/JP6149041B2/en active Active
- 2012-11-02 DK DK12829180.4T patent/DK2773326T3/en active
- 2012-11-05 TW TW101141082A patent/TWI618548B/en active
- 2012-11-05 TW TW106116691A patent/TWI626952B/en active
- 2012-11-05 TW TW101141084A patent/TWI615156B/en active
- 2012-11-05 US US13/669,217 patent/US8956572B2/en active Active
-
2017
- 2017-04-20 JP JP2017083327A patent/JP6442551B2/en active Active
-
2019
- 2019-03-11 HR HRP20190481TT patent/HRP20190481T1/en unknown
- 2019-03-28 CY CY20191100358T patent/CY1121495T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201904389T4 (en) | Method for producing lipid nucleic acid particles in a sterile manner. | |
CY1123208T1 (en) | CYCLIC BORONIC ACID ESTERS, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF | |
MY161726A (en) | Biological methods for preparing adipic acid | |
IL233019A0 (en) | System and method for locating sources of biological rhythm disorders | |
MX2013008850A (en) | Compositions and methods for treating cardiovascular diseases. | |
CR20130613A (en) | DENTAL TOOL AND GUIDE DEVICES | |
EP2496700A4 (en) | Nucleic acid-containing lipid particles and related methods | |
BR112013033972A2 (en) | "recombinant DNA constructs, methods for producing and using them, transgenic plant and seed, and method for producing hybrid seed and hybrid seed thus produced". | |
IT1394401B1 (en) | SYSTEM AND PROCEDURE TO FACILITATE THE TREATMENT AND PRODUCTION IN A FORCE OF WELL. | |
DK3311827T3 (en) | NANOPARTICLES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF AS CARRIERS FOR AMPHIPATHIC OR HYDROPHOBIC MOLECULES IN THE MEDICAL FIELD, INCLUDING CANCER TREATMENT, AS WELL AS FOOD-RELATED COMPOUNDS | |
EP2787082A4 (en) | Microorganism for simultaneously producing l-amino acid and riboflavin, and method for producing l-amino acid and riboflavin using same | |
SG11201404570WA (en) | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine | |
BR112013021775A2 (en) | corineform bacteria, and method for producing an l-amino acid | |
IN2015DN00924A (en) | ||
DE112013001147A5 (en) | Method and device for producing preforms | |
GB201102108D0 (en) | Diagnostic method | |
MX356270B (en) | Methods for decontaminating circuits for producing glucose polymers and hydrolysates of glucose polymers. | |
BR112014005383C8 (en) | bis-iminopyridine complex of lanthanides, catalytic system comprising said bis-iminopyridine complex and process for the (co)polymerization of conjugated dienes | |
ES2424811R1 (en) | System and method to calculate GHG emissions associated with the bioproduct industry. | |
BR112014031919A2 (en) | process for acetic acid production | |
WO2011151470A3 (en) | Methods and helper viruses for the generation of rna virus | |
DE112012000228A5 (en) | Device for producing upholstered hollow bodies | |
EP2886548A4 (en) | Method for producing borinic acid derivative, and novel borinic acid derivative | |
MX351765B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease. | |
RU2011119752A (en) | METHOD FOR ASSESSING THE SAFETY OF INTRODUCING COPPER NANOPARTICLES INTO THE ORGANISM |